Retatrutide is an investigational molecule. It is not an approved medicine in India, the UAE, or any other country, and it cannot be legally sold for human use. India status · UAE status
Every registered study and peer-reviewed publication referenced across this site, each linked to its primary record. Filter by phase, status or evidence type.
Showing all 20 entries.
Jastreboff AM, et al. New England Journal of Medicine. The full TRIUMPH-1 Phase 3 report. Abstract states 25.0% mean weight reduction at 12 mg versus 3.9% placebo (treatment-regimen estimand).
Jastreboff AM, et al. New England Journal of Medicine. 338 participants, 48 weeks. 17.5% mean reduction at the 24-week primary endpoint; 24.2% at 48 weeks.
Rosenstock J, et al. The Lancet. The Phase 2 diabetes trial, against placebo and dulaglutide. Full citation pending verification — we have not confirmed volume, pages and DOI from a primary record, so we cite the registry entry and describe design only.
80-week randomised, double-blind, placebo-controlled master trial in adults with obesity or overweight without diabetes. 2,339 randomised to 4 mg, 9 mg, 12 mg or placebo. Included knee osteoarthritis and sleep apnoea basket trials.
80-week placebo-controlled trial in adults with type 2 diabetes and obesity or overweight. 1,152 randomised. Weight reduction up to 20.8%; A1C reduction up to 1.6%. Includes Indian sites.
80-week placebo-controlled trial in severe obesity with established cardiovascular disease. 1,949 randomised 1:1:2. Weight reduction up to 22.6%. Cardiovascular event analyses had confidence intervals crossing 1.0.
68-week placebo-controlled trial in obesity with knee osteoarthritis. 445 randomised. Co-primary endpoints of WOMAC pain and weight. The programme's first Phase 3 readout, and its highest reported dysesthesia rate.
The only registered head-to-head comparison against tirzepatide in obesity. 800 adults, 80 weeks, percent body-weight change. The trial that will settle a question currently answered only by cross-trial guesswork.
Event-driven trial of about 10,000 participants examining major adverse cardiovascular and kidney events. The only study powered to answer the cardiovascular question. Includes Indian sites.
Phase 3b trial of retatrutide in the maintenance of weight reduction. 643 participants, primary endpoint at week 116. Addresses what happens after initial weight reduction.
586 participants with obesity or overweight and chronic low back pain. Co-primary endpoints of pain intensity and percent body-weight change at up to 72 weeks.
Phase 3b randomised, double-blind, placebo-controlled trial in 250 adults without type 2 diabetes who have obesity or overweight. Primary endpoint at week 56.
600 participants, comparing different dose-escalation schemes. Primary endpoint percent body-weight change at week 104. Relevant to how tolerability is managed in trial design.
537 adults with type 2 diabetes inadequately controlled with diet and exercise alone. Primary endpoint A1C change at week 40. Includes Indian sites. Completed January 2026.
1,250 adults with type 2 diabetes on metformin. Open-label, primary endpoint A1C at week 80 — not an obesity trial and not weight-focused.
320 adults with type 2 diabetes and moderate or severe renal impairment on basal insulin. Primary endpoint A1C at week 52.
Master protocol of multiple agents in about 4,500 adults with metabolic dysfunction-associated steatotic liver disease at increased risk of major adverse liver outcomes. Includes Indian sites.
48-week randomised, double-blind, placebo-controlled trial, United States only. 338 participants across six retatrutide arms and placebo. The foundation of the Phase 3 programme.
281 participants, against placebo and dulaglutide. Primary endpoint A1C change at 24 weeks. The only completed head-to-head against another incretin agent.
Single-ascending-dose study of safety, tolerability and pharmacokinetics in 45 healthy participants. The start of retatrutide's clinical programme. Twelve further Phase 1 studies followed.
No entries match those filters. Try resetting, or tell us what you were looking for.
About this index
This library indexes the studies and publications cited across this site. It is not a complete list of all 33 registered records — the thirteen Phase 1 studies are summarised collectively rather than listed individually. For the complete register, search ClinicalTrials.gov directly, or see our full programme overview.
Hi 👋 Welcome to Retatrutide India.
We document the published evidence on retatrutide — an investigational molecule that is not approved anywhere and cannot be legally sold.
What would you like to ask about? 😊
Opens WhatsApp · +1 672 273 0635
We cannot supply retatrutide, arrange access or give medical advice.